<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400881</article-id><article-id pub-id-type="pmc">PMC12094296</article-id><article-id pub-id-type="doi">10.7759/cureus.82715</article-id><article-categories><subj-group subj-group-type="heading"><subject>Other</subject></subj-group><subj-group><subject>Oncology</subject></subj-group><subj-group><subject>Quality Improvement</subject></subj-group></article-categories><title-group><article-title>An Innovative Approach to Target Lesion Progression in the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1: The Enaworu 25 mm Nadir Rule</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Enaworu</surname><given-names>Oghenetanure R</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, USA </aff><author-notes><corresp id="cor1">
Oghenetanure R. Enaworu <email>tanureenaworu@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>4</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>4</month><year>2025</year></pub-date><volume>17</volume><issue>4</issue><elocation-id>e82715</elocation-id><history><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Enaworu et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Enaworu et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/353893-an-innovative-approach-to-target-lesion-progression-in-the-response-evaluation-criteria-in-solid-tumors-recist-11-the-enaworu-25-mm-nadir-rule">This article is available from https://www.cureus.com/articles/353893-an-innovative-approach-to-target-lesion-progression-in-the-response-evaluation-criteria-in-solid-tumors-recist-11-the-enaworu-25-mm-nadir-rule</self-uri><abstract><p>The Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 remains the benchmark for evaluating tumour response within clinical trials and oncological practice. It defines disease progression in target lesions as a &#x02265;20% increase in the sum of the longest diameters (SLD), accompanied by an additional absolute increase of &#x02265;5 mm from the nadir. While these dual criteria enhance diagnostic accuracy, their simultaneous application poses several challenges, including the complexity of lesion tracking and potential ambiguity in assessing progression for smaller target lesions. This study presents Enaworu&#x02019;s 25 mm nadir rule, a novel and standardised approach designed to streamline the assessment of target lesion progression. According to this rule, lesions with a nadir of less than 25 mm progress based solely on an absolute increase of 5 mm, whereas lesions with a nadir of 25 mm or more will progress based solely on a 20% increase from the nadir, thereby eliminating the necessity of applying both criteria concurrently. A simulated dataset comprising 1,000 patients, with nadir tumour sizes varying from 0.03 mm to 69.96 mm, was employed to compare progression classification under RECIST 1.1 and the 25 mm nadir rule. The results indicated identical classification outcomes, with 255 patients (25.5%) satisfying the progression criteria under both methodologies. The simplified rule maintained diagnostic accuracy while alleviating administrative burdens and enhancing clarity. The Enaworu&#x02019;s 25 mm nadir rule constitutes a practical refinement of RECIST 1.1, optimising workflow efficiency, reducing ambiguity, and ensuring consistency within clinical and research settings.</p></abstract><kwd-group kwd-group-type="author"><kwd>clinical trials</kwd><kwd>lesion assessment</kwd><kwd>nadir</kwd><kwd>oncology</kwd><kwd>recist 1.1</kwd><kwd>target lesion progression</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The Response Evaluation Criteria in Solid Tumors (RECIST) 1.1&#x000a0;[<xref rid="REF1" ref-type="bibr">1</xref>]&#x000a0;provides a standardised framework for assessing tumour response, a key component in clinical trials and routine oncologic practice. Under RECIST 1.1, disease progression in target lesions is defined by a &#x02265;20% increase in the sum of the longest diameters (SLD) of target lesions, with an additional absolute increase of &#x02265;5 mm from the nadir (smallest recorded SLD)&#x000a0;[<xref rid="REF2" ref-type="bibr">2</xref>]. The inclusion of the 5 mm absolute increase criterion in RECIST 1.1 was to prevent the premature classification of progressive disease (PD) in cases where the baseline tumour burden is small&#x000a0;[<xref rid="REF3" ref-type="bibr">3</xref>]. While these dual criteria improve diagnostic accuracy, their concurrent application presents practical challenges, requiring meticulous tracking and precise calculations that may hinder workflow efficiency. A study analysing data from over 50 clinical trials across multiple malignancies highlighted this issue as a key challenge in RECIST 1.1&#x000a0;[<xref rid="REF4" ref-type="bibr">4</xref>]. Clinicians and researchers must assess a 20% increase and an absolute increase of at least 5 mm to determine progression. This can introduce ambiguity, particularly when small target lesions do not meet the 5 mm threshold despite a 20% increase. This raises an important question: At what point should a lesion be considered &#x0201c;small&#x0201d; in this context?</p><p>This study proposes Enaworu&#x02019;s 25 mm nadir rule to address these challenges, which provides a standardised approach to optimising target lesion progression assessment. Under this rule, for lesions with a nadir &#x0003c;25 mm, the progression threshold will be defined solely by an absolute increase of 5 mm, while for lesions with a nadir &#x02265;25 mm, only the 20% increase criterion will be applied. For example, for lesions with a nadir of 24 mm and 30 mm, the progression thresholds will be set at 29 mm and 36 mm, respectively. This modification eliminates the need to apply both criteria, streamlining the assessment process while preserving diagnostic accuracy and reducing ambiguity.</p><p>Previous studies&#x000a0;[<xref rid="REF5" ref-type="bibr">5</xref>-<xref rid="REF8" ref-type="bibr">8</xref>]&#x000a0;have refined RECIST 1.1, clarified its limitations, and explored challenges in data extraction and interpretation in clinical trials. Other studies&#x000a0;[<xref rid="REF9" ref-type="bibr">9</xref>-<xref rid="REF13" ref-type="bibr">13</xref>]&#x000a0;have proposed theoretical frameworks and alternative progression methods; however, none have conceptualised a threshold for target lesion progression based on either a 20% increase or a 5 mm absolute increase, rather than requiring both. The 25 mm nadir rule addresses this gap by establishing a standardised threshold that simplifies progression assessment while maintaining diagnostic accuracy.</p><p>This study aims to compare the assessments of target lesion progression between the proposed Enaworu&#x02019;s 25 mm nadir rule and the traditional RECIST 1.1 to determine whether both methods yield comparable outcomes.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Mathematical model equation and rationale of the 25 mm threshold</p><p>To identify the critical point at which the two progression criteria of RECIST 1.1 converge, we derived the following equation:</p><p>
<inline-formula>
<tex-math id="M174784694613772">\begin{document} 1.2 \times N = N + 5 \text{mm} \end{document}</tex-math>
</inline-formula>
</p><p>
<inline-formula>
<tex-math id="M17478469461382864">\begin{document} 1.2 \times N - N = 5 \text{mm} \end{document}</tex-math>
</inline-formula>
</p><p>
<inline-formula>
<tex-math id="M1747846946138743">\begin{document} (1.2 - 1) \times N = 5 \text{mm} \end{document}</tex-math>
</inline-formula>
</p><p>
<inline-formula>
<tex-math id="M17478469461392066">\begin{document} 0.2 \times N = 5 \text{mm} \end{document}</tex-math>
</inline-formula>
</p><p>
<inline-formula>
<tex-math id="M1747846946139654">\begin{document} N = \frac{5 \text{mm}}{0.2} \end{document}</tex-math>
</inline-formula>
</p><p>
<inline-formula>
<tex-math id="M17478469461403081">\begin{document} N = 25 \text{mm} \end{document}</tex-math>
</inline-formula>
</p><p>In this equation, &#x0201c;1.2 &#x000d7; <italic>N</italic>&#x0201d; denotes the calculation for a 20% rise in tumour size (with <italic>N</italic> representing the nadir in mm). The expression &#x0201c;<italic>N</italic> + 5&#x0201d; indicates the required 5 mm increase from the nadir, as the RECIST 1.1 criteria stipulate&#x000a0;to signify progression. When <italic>N</italic> equals 25 mm, the criteria for a 20% increase and the absolute 5 mm increase align. A nadir of 25 mm marks the key point where a 20% rise corresponds to a 5 mm absolute increase, satisfying both the percentage and absolute progression standards of RECIST 1.1.</p><p>Study design and population</p><p>This study utilised a simulated dataset to evaluate target lesion progression based on the RECIST 1.1 criteria and the 25 mm nadir rule. The dataset was generated to represent a cohort of 1,000 patients, with the distribution of baseline nadir tumour sizes (measured in millimetres) ranging from 0.03 to 69.96. To assess the impact of the critical threshold, the simulated dataset included nadir values of 24.9 mm and 25 mm, highlighting a potential shift in progression criteria based on tumour size.</p><p>Progression Criteria</p><p>Two distinct criteria for tumour progression were employed in the dataset analysis. Firstly, the RECIST 1.1 criteria stipulate that tumour progression is defined as an increase of 20% or more from the nadir measurement, accompanied by a minimum absolute increase of 5 mm. Secondly, the 25 mm nadir rule was implemented, whereby tumours with a nadir size of less than 25 mm are deemed progressive if they demonstrate an absolute increment of at least 5 mm. In contrast, tumours with a nadir size of 25 mm or more significant are classified as progressive based on a 20% or greater increase in size. For this study, the outcomes were categorised into progressive and non-progressive diseases.</p><p>Data Generation and Statistical Analysis</p><p>Tumour sizes were generated randomly for each patient, utilising a uniform distribution. Subsequently, follow-up tumour sizes were simulated based on a percentage increase, with the follow-up size determined as a function of the baseline nadir and a random increase ranging from 0% to 30%. To comprehensively evaluate tumour progression, the RECIST 1.1 and the 25 mm nadir rule were systematically applied across the entire cohort. A visual comparison of both progression criteria was presented through side-by-side scatter plots. Furthermore, an enlarged visualisation centred on the critical nadir size range (20 mm to 30 mm) was provided, particularly underscoring tumours with 24.9 mm and 25 mm measurements, where the divergence between the two criteria is most significant. Data generation and statistical analyses were conducted utilising R&#x000a0;version 4.2.3 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec><sec sec-type="results"><title>Results</title><p>The distribution of baseline tumour sizes revealed a minimum value of 0.03 mm, a first quartile (Q1) of 17.75 mm, a median of 34.30 mm, a mean of 34.81 mm, a third quartile (Q3) of 52.28 mm, and a maximum value of 69.96 mm. These figures illustrate a wide range of tumour sizes, with the majority falling between 17.75 mm and 52.28 mm. The follow-up distribution of tumour sizes was similarly structured.</p><p>Tumour progression analysis</p><p>Table&#x000a0;<xref rid="TAB1" ref-type="table">1</xref>&#x000a0;presents a comparative analysis of tumour progression classification under RECIST 1.1 and the 25 mm nadir rule, summarising the percentage of patients meeting the progression criteria for each method.</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Comparison of tumour progression classification between RECIST 1.1 and Enaworu's 25 mm nadir rule.</title><p>RECIST: Response Evaluation Criteria in Solid Tumors.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Progression status</td><td rowspan="1" colspan="1">RECIST 1.1 (n, %)</td><td rowspan="1" colspan="1">Enaworu&#x02019;s 25 mm nadir rule (n, %)</td></tr><tr><td rowspan="1" colspan="1">Progression (True)</td><td rowspan="1" colspan="1">255 (25.5%)</td><td rowspan="1" colspan="1">255 (25.5%)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">No progression (False)</td><td rowspan="1" colspan="1">745 (74.5%)</td><td rowspan="1" colspan="1">745 (74.5%)</td></tr></tbody></table></table-wrap><p>Analysis revealed that using the RECIST 1.1 progression criteria for target lesion, 255 patients (25.5%) showed progressive disease, while 745 patients (74.5%) were non-progressive. Conversely, the 25 mm nadir rule showed similar results, demonstrating complete concordance with RECIST 1.1.</p><p>Critical Tumour Size Threshold (24.9 mm and 25 mm)</p><p>Table&#x000a0;<xref rid="TAB2" ref-type="table">2</xref>&#x000a0;below shows the progression classifications for both methods at these specific tumour sizes. RECIST 1.1 and the 25 mm nadir rule classified tumours identically at these critical thresholds, reinforcing their overall concordance in progression assessment.</p><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>Tumour progression classification at critical nadir thresholds.</title><p>RECIST: Response Evaluation Criteria in Solid Tumors.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Nadir size (mm)</td><td rowspan="1" colspan="1">RECIST 1.1, progression (n, %)</td><td rowspan="1" colspan="1">RECIST 1.1, no progression (n, %)</td><td rowspan="1" colspan="1">Enaworu's 25 mm nadir rule, progression (n, %)</td><td rowspan="1" colspan="1">Enaworu's 25 mm nadir rule, no progression (n, %)</td></tr><tr><td rowspan="1" colspan="1">24.9</td><td rowspan="1" colspan="1">50 (50%)</td><td rowspan="1" colspan="1">50 (50%)</td><td rowspan="1" colspan="1">50 (50%)</td><td rowspan="1" colspan="1">50 (50%)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">70 (70%)</td><td rowspan="1" colspan="1">30 (30%)</td><td rowspan="1" colspan="1">70 (70%)</td><td rowspan="1" colspan="1">30 (30%)</td></tr></tbody></table></table-wrap><p>Figure&#x000a0;<xref rid="FIG1" ref-type="fig">1</xref>&#x000a0;displays both methods&#x02019; side-by-side scatter plots comparing baseline tumour size (nadir) with follow-up tumour size (in mm). Each data point represents a patient and is colour-coded to indicate progression status (red for progression, green for no progression). This visualisation highlights the concordance between the two methods in classifying target lesion progression. Figure&#x000a0;<xref rid="FIG2" ref-type="fig">2</xref>&#x000a0;emphasises the critical tumour size range of 20 mm to 30 mm, further demonstrating the alignment between the two methods.</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>Comparison of tumour progression between RECIST 1.1 and Enaworu's 25 mm threshold rule, illustrating changes in tumour size and progression status.</title><p>RECIST: Response Evaluation Criteria in Solid Tumors.</p></caption><graphic xlink:href="cureus-0017-00000082715-i01" position="float"/></fig><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>Comparison of tumour progression around the critical values of 24.9 mm and 25 mm.</title><p>RECIST: Response Evaluation Criteria in Solid Tumors.</p></caption><graphic xlink:href="cureus-0017-00000082715-i02" position="float"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>This study showed that the 25 mm nadir rule aligns with RECIST 1.1 in classifying target lesion progression. Both methods identified 25.5% of patients with progression and 74.5% with non-progression, demonstrating complete concordance. This suggests that the 25 mm nadir rule can replicate the progression classification provided by RECIST 1.1 while offering a simplified approach to tumour assessment, particularly for small lesions. The findings support the accuracy and reliability of RECIST 1.1, as it has been shown to provide consistent and reproducible results in response assessment&#x000a0;[<xref rid="REF14" ref-type="bibr">14</xref>].</p><p>The Enaworu&#x02019;s 25 mm nadir rule stipulates that, under RECIST 1.1 criteria, the progression threshold for target lesions exhibiting a nadir measurement of less than 25 mm is solely determined by an absolute increase of 5 mm. Conversely, for target lesions with a 25 mm or greater nadir measurement, the progression threshold is defined by a 20% increase from the nadir. The rationale is based on the observation that if the nadir measurement is less than 25 mm, a 20% increase yields a value below 5 mm, failing to meet the RECIST 1.1 criteria for target lesion progression. However, a 5 mm increase is more practical because it automatically satisfies the 5 mm minimum and the desired 20% increase. In contrast, for target lesions with a nadir of 25 mm or more, a 20% increase will invariably meet or exceed the 5 mm threshold, rendering the 5 mm rule redundant.</p><p>The findings of this study align with existing literature advocating for simplified tumour progression assessment methods, particularly in the context of personalised tumour response evaluation&#x000a0;[<xref rid="REF15" ref-type="bibr">15</xref>].&#x000a0;By offering a clear, threshold-based solution, the 25 mm nadir rule eliminates the ambiguity of applying the dual criteria of RECIST 1.1, thereby enhancing workflow efficiency. This approach improves efficiency, similar to a study that showed significant reductions in nonconformities and time savings in radiology workflows&#x000a0;[<xref rid="REF16" ref-type="bibr">16</xref>]. While the study [<xref rid="REF16" ref-type="bibr">16</xref>] focused on optimising radiological processes, the 25 mm nadir rule simplifies progression assessment, reducing the complexity of RECIST 1.1 criteria, ultimately enhancing both efficiency and accuracy.</p><p>The 25 mm nadir rule can be included in RECIST 1.1 worksheets used in clinical and trial environments to define a progressive disease (PD) threshold. This adjustment minimises the chances of errors, creating a more intuitive and clinically relevant framework for progression assessment. Additionally, integrating the 25 mm nadir rule into AI-driven RECIST calculators marks a significant step in simplifying tumour progression evaluations in clinical oncology&#x000a0;[<xref rid="REF17" ref-type="bibr">17</xref>]. These tools can automate the rule&#x02019;s application, effectively managing extensive datasets of tumour measurements and equipping clinicians with prompt, dependable, and uniform outcomes.</p><p>However, like any novel approach, Enaworu&#x02019;s proposed 25 mm nadir rule has limitations. The study relied on simulated data. Future research using real-world clinical datasets would be beneficial for validating the rule&#x02019;s applicability across a broader range of target lesions and patient populations&#x000a0;[<xref rid="REF18" ref-type="bibr">18</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The 25 mm nadir rule presents a practical and simplified approach to tumour progression assessment, addressing key challenges in the RECIST 1.1 criteria. By establishing a single threshold for progression, it eliminates the complexities of using both absolute and relative measures simultaneously. Our findings demonstrate that this method aligns with RECIST 1.1 regarding progression outcomes. This approach can potentially improve clinical decision-making, particularly in routine practice and clinical trials, by streamlining response evaluations. Further&#x000a0;validation in diverse, real-world settings is essential to fully assess its impact and potential integration into clinical workflows.</p></sec></body><back><ack><p>I sincerely acknowledge Mehir Tharani for the insightful discussion that sparked the idea for this study. His contributions were instrumental in shaping the concept of the Enaworu&#x02019;s 25 mm Nadir Rule. Simulated data were used and will be made available on request. I would like to acknowledge the use of AI tools in the editing of this manuscript, which assisted in refining the clarity and style of the text.</p></ack><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> All authors have confirmed that this study did not involve human participants or tissue.</p><p><bold>Animal subjects:</bold> All authors have confirmed that this study did not involve animal subjects or tissue.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Oghenetanure R. Enaworu</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Oghenetanure R. Enaworu</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Oghenetanure R. Enaworu</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Oghenetanure R. Enaworu</p><p><bold>Supervision:</bold>&#x000a0; Oghenetanure R. Enaworu</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title><source>Eur J Cancer</source><person-group>
<name><surname>Eisenhauer</surname><given-names>EA</given-names></name>
<name><surname>Therasse</surname><given-names>P</given-names></name>
<name><surname>Bogaerts</surname><given-names>J</given-names></name>
<etal/>
</person-group><fpage>228</fpage><lpage>247</lpage><volume>45</volume><year>2009</year><pub-id pub-id-type="pmid">19097774</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>A radiologist's guide to Response Evaluation Criteria in Solid Tumors</article-title><source>Curr Probl Diagn Radiol</source><person-group>
<name><surname>Lalchandani</surname><given-names>UR</given-names></name>
<name><surname>Sahai</surname><given-names>V</given-names></name>
<name><surname>Hersberger</surname><given-names>K</given-names></name>
<name><surname>Francis</surname><given-names>IR</given-names></name>
<name><surname>Wasnik</surname><given-names>AP</given-names></name>
</person-group><fpage>576</fpage><lpage>585</lpage><volume>48</volume><year>2019</year><pub-id pub-id-type="pmid">30181058</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="webpage"><article-title>RECIST 1.1 - the basics: Response Evaluation Criteria in Solid Tumors</article-title><date-in-citation content-type="access-date">
<month>3</month>
<year>2025</year>
</date-in-citation><person-group>
<name><surname>Smits</surname><given-names>F</given-names></name>
<name><surname>Dirksen</surname><given-names>M</given-names></name>
<name><surname>Schoots</surname><given-names>I</given-names></name>
</person-group><year>2024</year><uri xlink:href="https://radiologyassistant.nl/more/recist-1-1/recist-1-1-1">https://radiologyassistant.nl/more/recist-1-1/recist-1-1-1</uri></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Common pitfalls of RECIST 1.1 application in clinical trials</article-title><source>Eur J Cancer</source><person-group>
<name><surname>Teslenko</surname><given-names>I</given-names></name>
<name><surname>Belotserkovsky</surname><given-names>M</given-names></name>
</person-group><fpage>0</fpage><volume>51</volume><year>2015</year></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>RECIST 1.1&#x02014;update and clarification: from the RECIST Committee</article-title><source>Eur J Cancer</source><person-group>
<name><surname>Schwartz</surname><given-names>LH</given-names></name>
<name><surname>Liti&#x000e8;re</surname><given-names>S</given-names></name>
<name><surname>de Vries</surname><given-names>E</given-names></name>
<etal/>
</person-group><fpage>132</fpage><lpage>137</lpage><volume>62</volume><year>2016</year><pub-id pub-id-type="pmid">27189322</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>RECIST 1.1 - standardisation and disease-specific adaptations: perspectives from the RECIST Working Group</article-title><source>Eur J Cancer</source><person-group>
<name><surname>Schwartz</surname><given-names>LH</given-names></name>
<name><surname>Seymour</surname><given-names>L</given-names></name>
<name><surname>Liti&#x000e8;re</surname><given-names>S</given-names></name>
<etal/>
</person-group><fpage>138</fpage><lpage>145</lpage><volume>62</volume><year>2016</year><pub-id pub-id-type="pmid">27237360</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Advances in oncological treatment: limitations of RECIST 1.1 criteria</article-title><source>Q J Nucl Med Mol Imaging</source><person-group>
<name><surname>Grimaldi</surname><given-names>S</given-names></name>
<name><surname>Terroir</surname><given-names>M</given-names></name>
<name><surname>Caramella</surname><given-names>C</given-names></name>
</person-group><fpage>129</fpage><lpage>139</lpage><volume>62</volume><year>2018</year><pub-id pub-id-type="pmid">29166754</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Pitfalls in RECIST data extraction for clinical trials: beyond the basics</article-title><source>Acad Radiol</source><person-group>
<name><surname>Abramson</surname><given-names>RG</given-names></name>
<name><surname>McGhee</surname><given-names>CR</given-names></name>
<name><surname>Lakomkin</surname><given-names>N</given-names></name>
<name><surname>Arteaga</surname><given-names>CL</given-names></name>
</person-group><fpage>779</fpage><lpage>786</lpage><volume>22</volume><year>2015</year><pub-id pub-id-type="pmid">25794800</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Superiority of bi-dimensional measurements compared to RECIST in measuring response of metastatic brain tumors</article-title><source>J Clin Oncol</source><person-group>
<name><surname>Kilpatrick</surname><given-names>MR</given-names></name>
<name><surname>Linn</surname><given-names>NU</given-names></name>
<name><surname>Smith</surname><given-names>JK</given-names></name>
<name><surname>Winer</surname><given-names>EP</given-names></name>
<name><surname>Bullitt</surname><given-names>E</given-names></name>
<name><surname>Carey</surname><given-names>LA</given-names></name>
<name><surname>Ewend</surname><given-names>MG</given-names></name>
</person-group><fpage>1542</fpage><volume>24</volume><year>2006</year><pub-id pub-id-type="pmid">16575005</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy</article-title><source>Radiol Oncol</source><person-group>
<name><surname>Vrankar</surname><given-names>M</given-names></name>
<name><surname>Unk</surname><given-names>M</given-names></name>
</person-group><fpage>365</fpage><lpage>369</lpage><volume>52</volume><year>2018</year><pub-id pub-id-type="pmid">30367809</pub-id>
</element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Tumor therapeutics in the era of "RECIST": past, current insights, and future prospects</article-title><source>Oncol Rev</source><person-group>
<name><surname>Xu</surname><given-names>Z</given-names></name>
<name><surname>Jiang</surname><given-names>G</given-names></name>
<name><surname>Dai</surname><given-names>J</given-names></name>
</person-group><fpage>1435922</fpage><volume>18</volume><year>2024</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/39493769/">https://pubmed.ncbi.nlm.nih.gov/39493769/</uri><pub-id pub-id-type="pmid">39493769</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors</article-title><source>J Nucl Med</source><person-group>
<name><surname>Wahl</surname><given-names>RL</given-names></name>
<name><surname>Jacene</surname><given-names>H</given-names></name>
<name><surname>Kasamon</surname><given-names>Y</given-names></name>
<name><surname>Lodge</surname><given-names>MA</given-names></name>
</person-group><fpage>122</fpage><lpage>150</lpage><volume>50</volume><year>2009</year></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Objective response rate assessment in oncology: current situation and future expectations</article-title><source>World J Clin Oncol</source><person-group>
<name><surname>Aykan</surname><given-names>NF</given-names></name>
<name><surname>&#x000d6;zatl&#x00131;</surname><given-names>T</given-names></name>
</person-group><fpage>53</fpage><lpage>73</lpage><volume>11</volume><year>2020</year><pub-id pub-id-type="pmid">32133275</pub-id>
</element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy</article-title><source>AJR Am J Roentgenol</source><person-group>
<name><surname>Nishino</surname><given-names>M</given-names></name>
<name><surname>Jackman</surname><given-names>DM</given-names></name>
<name><surname>Hatabu</surname><given-names>H</given-names></name>
<etal/>
</person-group><fpage>0</fpage><lpage>8</lpage><volume>195</volume><year>2010</year></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST</article-title><source>AJR Am J Roentgenol</source><person-group>
<name><surname>Nishino</surname><given-names>M</given-names></name>
<name><surname>Jagannathan</surname><given-names>JP</given-names></name>
<name><surname>Krajewski</surname><given-names>KM</given-names></name>
<name><surname>O'Regan</surname><given-names>K</given-names></name>
<name><surname>Hatabu</surname><given-names>H</given-names></name>
<name><surname>Shapiro</surname><given-names>G</given-names></name>
<name><surname>Ramaiya</surname><given-names>NH</given-names></name>
</person-group><fpage>737</fpage><lpage>745</lpage><volume>198</volume><year>2012</year><pub-id pub-id-type="pmid">22451534</pub-id>
</element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Radiology workflow for RECIST assessment in clinical trials: can we reconcile time-efficiency and quality?</article-title><source>Eur J Radiol</source><person-group>
<name><surname>Beaumont</surname><given-names>H</given-names></name>
<name><surname>Bertrand</surname><given-names>AS</given-names></name>
<name><surname>Klifa</surname><given-names>C</given-names></name>
<name><surname>Patriti</surname><given-names>S</given-names></name>
<name><surname>Cippolini</surname><given-names>S</given-names></name>
<name><surname>Lovera</surname><given-names>C</given-names></name>
<name><surname>Iannessi</surname><given-names>A</given-names></name>
</person-group><fpage>257</fpage><lpage>263</lpage><volume>118</volume><year>2019</year><pub-id pub-id-type="pmid">31439252</pub-id>
</element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Automated quantitative assessment of oncological disease progression using deep learning</article-title><source>Ann Transl Med</source><person-group>
<name><surname>Barash</surname><given-names>Y</given-names></name>
<name><surname>Klang</surname><given-names>E</given-names></name>
</person-group><fpage>0</fpage><volume>7</volume><year>2019</year></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Real-world data: a brief review of the methods, applications, challenges and opportunities</article-title><source>BMC Med Res Methodol</source><person-group>
<name><surname>Liu</surname><given-names>F</given-names></name>
<name><surname>Panagiotakos</surname><given-names>D</given-names></name>
</person-group><fpage>287</fpage><volume>22</volume><year>2022</year><pub-id pub-id-type="pmid">36335315</pub-id>
</element-citation></ref></ref-list></back></article>